These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 30630516)

  • 1. Clinical and positron emission tomography responses to long-term high-dose interferon-α treatment among patients with Erdheim-Chester disease.
    Cao XX; Niu N; Sun J; Cai H; Wang FD; Wang YN; Duan MH; Zhou DB; Li J
    Orphanet J Rare Dis; 2019 Jan; 14(1):11. PubMed ID: 30630516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.
    Diamond EL; Subbiah V; Lockhart AC; Blay JY; Puzanov I; Chau I; Raje NS; Wolf J; Erinjeri JP; Torrisi J; Lacouture M; Elez E; Martínez-Valle F; Durham B; Arcila ME; Ulaner G; Abdel-Wahab O; Pitcher B; Makrutzki M; Riehl T; Baselga J; Hyman DM
    JAMA Oncol; 2018 Mar; 4(3):384-388. PubMed ID: 29188284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurologic and oncologic features of Erdheim-Chester disease: a 30-patient series.
    Bhatia A; Hatzoglou V; Ulaner G; Rampal R; Hyman DM; Abdel-Wahab O; Durham BH; Dogan A; Ozkaya N; Yabe M; Petrova-Drus K; Panageas KS; Reiner A; Rosenblum M; Diamond EL
    Neuro Oncol; 2020 Jul; 22(7):979-992. PubMed ID: 31950179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease.
    Haroche J; Cohen-Aubart F; Emile JF; Maksud P; Drier A; Tolédano D; Barete S; Charlotte F; Cluzel P; Donadieu J; Benameur N; Grenier PA; Besnard S; Ory JP; Lifermann F; Idbaih A; Granel B; Graffin B; Hervier B; Arnaud L; Amoura Z
    J Clin Oncol; 2015 Feb; 33(5):411-8. PubMed ID: 25422482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of clinicopathologic characteristics and the BRAF V600E mutation in Erdheim-Chester disease among Chinese adults.
    Cao XX; Sun J; Li J; Zhong DR; Niu N; Duan MH; Liang ZY; Zhou DB
    Ann Hematol; 2016 Apr; 95(5):745-50. PubMed ID: 26858028
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Young JR; Johnson GB; Murphy RC; Go RS; Broski SM
    J Nucl Med; 2018 May; 59(5):774-779. PubMed ID: 29097410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. (18)F-FDG positron emission tomography/computed tomography and (99m)Tc-MDP skeletal scintigraphy in a case of Erdheim-Chester disease.
    Asabella AN; Cimmino A; Altini C; Notaristefano A; Rubini G
    Hell J Nucl Med; 2011; 14(3):311-2. PubMed ID: 22087457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 18F-fluorodeoxyglucose-positron emission tomography scanning is more useful in followup than in the initial assessment of patients with Erdheim-Chester disease.
    Arnaud L; Malek Z; Archambaud F; Kas A; Toledano D; Drier A; Zeitoun D; Cluzel P; Grenier PA; Chiras J; Piette JC; Amoura Z; Haroche J
    Arthritis Rheum; 2009 Oct; 60(10):3128-38. PubMed ID: 19790052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy and safety of vemurafenib in the treatment of BRAF(V600E)-mutated Erdheim-Chester disease].
    Liu T; He TH; Niu N; Li J; Zhou DB; Cao XX
    Zhonghua Xue Ye Xue Za Zhi; 2021 Sep; 42(9):752-756. PubMed ID: 34753230
    [No Abstract]   [Full Text] [Related]  

  • 10. Dramatic efficacy of dabrafenib in Erdheim-Chester disease (ECD): a pediatric patient with multiple large intracranial ECD lesions hidden by refractory Langerhans cell histiocytosis.
    Hao X; Feng R; Bi Y; Liu Y; Li C; Lu T; Tian Y
    J Neurosurg Pediatr; 2019 Jan; 23(1):48-53. PubMed ID: 30265230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical spectrum and prognostic factors of Erdheim-Chester disease and mixed Langerhans cell histiocytosis and Erdheim-Chester disease.
    Dai JW; Lin H; Chang L; Li J; Zhou DB; Cao XX
    Ann Hematol; 2023 Dec; 102(12):3335-3343. PubMed ID: 37922006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Skeletal involvement in Erdheim-Chester disease: Multimodality imaging features and association with the BRAF
    Nikpanah M; Dehghani Firouzabadi F; Farhadi F; Mirmomen SM; Ahlman MA; Huda F; Millo C; Saboury B; Paschall AK; Gahl WA; Estrada-Veras JI; Turkbey E; Jones EC; O'Brien K; Malayeri AA
    Clin Imaging; 2024 Feb; 106():110067. PubMed ID: 38128404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The histiocytosis Erdheim-Chester disease is an inflammatory myeloid neoplasm.
    Haroche J; Cohen-Aubart F; Charlotte F; Maksud P; Grenier PA; Cluzel P; Mathian A; Emile JF; Amoura Z
    Expert Rev Clin Immunol; 2015; 11(9):1033-42. PubMed ID: 26197238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Usefulness of combined positron emission tomography and computed tomography imaging in Erdheim-Chester disease].
    Girszyn N; Arnaud L; Villain D; Kahn JE; Piette AM; Bletry O
    Rev Med Interne; 2007 Nov; 28(11):770-4. PubMed ID: 17629593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAF V600E mutation in Juvenile Xanthogranuloma family neoplasms of the central nervous system (CNS-JXG): a revised diagnostic algorithm to include pediatric Erdheim-Chester disease.
    Picarsic J; Pysher T; Zhou H; Fluchel M; Pettit T; Whitehead M; Surrey LF; Harding B; Goldstein G; Fellig Y; Weintraub M; Mobley BC; Sharples PM; Sulis ML; Diamond EL; Jaffe R; Shekdar K; Santi M
    Acta Neuropathol Commun; 2019 Nov; 7(1):168. PubMed ID: 31685033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evaluation of five years of treatment of Erdheim-Chester disease with anakinra: case report and overview of literature].
    Adam Z; Petrášová H; Řehák Z; Koukalová R; Krejčí M; Pour L; Vetešníková E; Čermák A; Ševčíková S; Szturz P; Král Z; Mayer J
    Vnitr Lek; 2016; 62(10):820-832. PubMed ID: 27900869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful treatment with cladribine of Erdheim-Chester disease with orbital and central nervous system involvement developing after treatment of Langerhans cell histiocytosis.
    Perić P; Antić B; Knezević-Usaj S; Radić-Tasić O; Radovinović-Tasić S; Vasić-Vilić J; Sekulović L; Tarabar O; Tukić L; Jovandić S; Magić Z
    Vojnosanit Pregl; 2016 Jan; 73(1):83-7. PubMed ID: 26964390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abdominal involvement in Erdheim-Chester disease (ECD): MRI and CT imaging findings and their association with BRAF
    Nikpanah M; Kim L; Mirmomen SM; Symons R; Papageorgiou I; Gahl WA; O'Brien K; Estrada-Veras JI; Malayeri AA
    Eur Radiol; 2018 Sep; 28(9):3751-3759. PubMed ID: 29556768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Erdheim-Chester disease (ECD), an inflammatory myeloid neoplasia].
    Haroche J; Papo M; Cohen-Aubart F; Charlotte F; Maksud P; Grenier PA; Cluzel P; Mathian A; Emile JF; Amoura Z
    Presse Med; 2017 Jan; 46(1):96-106. PubMed ID: 27234902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of 2-[
    Pudis M; Palomar-Muñoz A; Solanich-Moreno X; Robles-Barba JJ; Rocamora-Blanch G; Rodríguez-Bel L; Narváez JA; Cortés-Romera M
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2024; 43(1):14-22. PubMed ID: 37804884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.